Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer
ConclusionQuantitative assessment of [99mTc]NM-01 SPECT/CT in NSCLC, using SUVmax of malignant primary or metastatic lesions and their ratios with healthy reference tissues, demonstrated good or excellent inter- and intra-rater agreement in this study. Further validation with ongoing and future larger cohort studies is now warranted.Clinical trial registrationClinicalTrials.gov identifier no. NCT04436406 (registered 18th June 2020; available athttps://clinicaltrials.gov/ct2/show/NCT04436406) and NCT04992715 (registered 5th August 2021; available athttps://clinicaltrials.gov/ct2/show/NCT04992715).
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | SPECT | Study